Taysha Gene Therapies, Inc. (TSHA)
Automate Your Wheel Strategy on TSHA
With Tiblio's Option Bot, you can configure your own wheel strategy including TSHA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TSHA
- Rev/Share 0.0268
- Book/Share 0.2044
- PB 12.9618
- Debt/Equity 0.3104
- CurrentRatio 5.3512
- ROIC -0.7622
- MktCap 693054497.0
- FreeCF/Share -0.3121
- PFCF -8.2449
- PE -8.2251
- Debt/Assets 0.1235
- DivYield 0
- ROE -1.0704
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with …
Read More
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relations Sean P. Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham and Company Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Biren Amin - Piper Sandler Whitney Ijem - Canaccord Genuity Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - Citizens Malcolm Hoffman - BMO …
Read More
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Read More
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 822,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with …
Read More
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) …
Read More
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call Details Wednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central Time Toll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-presentations About Taysha Gene Therapies Taysha Gene Therapies …
Read More
About Taysha Gene Therapies, Inc. (TSHA)
- IPO Date 2020-09-24
- Website https://www.tayshagtx.com
- Industry Biotechnology
- CEO Mr. Sean P. Nolan
- Employees 73